Kane Biotech Receives Decisions to Grant for Two European Patents Providing Broad Protection of coactiv+™ Technology for Wound Care, Skin Infections and Personal Care Formulations
The allowed claims cover composition of matter for the company's proprietary formulations for use in treating wounds and skin infections and in personal care formulations.
- The allowed claims cover composition of matter for the company's proprietary formulations for use in treating wounds and skin infections and in personal care formulations.
- A Decision to Grant is the European Examiners confirmation that the European Patent Office has decided to grant Kane the patent and has set the grant date.
- "These patents are important additions to the existing portfolio covering Kanes coactiv+ technology platform," saidGordon Guay, the company's Chief Scientific Officer.
- Its multi-functional and gentle formulation makes it a perfect companion treatment to DispersinB Hydrogel, also part of the Kane Biotech antibiofilm wound care portfolio.